Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 26

Results For "Inc."

396 News Found

MEI Pharma appoints Anne Frese as Chief People Officer
People | June 24, 2022

MEI Pharma appoints Anne Frese as Chief People Officer

Most recently, she served as chief human resources officer at Vyripharm Enterprises.


Briefs: Marksans Pharma and Alkem
News | June 22, 2022

Briefs: Marksans Pharma and Alkem

The US FDA had conducted an inspection of Alkem Laboratories Limited's manufacturing facility located at St. Louis, USA.


Dr. Reddy's Lab launches sorafenib tablets in US
News | June 15, 2022

Dr. Reddy's Lab launches sorafenib tablets in US

Dr. Reddy's Sorafenib Tablets, USP, are available in 200 mg tablets in bottle count sizes of 120.


CCI approves sale of biosimilars portfolio of Viatris to Biocon Biologics
News | June 15, 2022

CCI approves sale of biosimilars portfolio of Viatris to Biocon Biologics

The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics


Dr. Bharati Pravin Pawar launches Intensified Diarrhoea Control Fortnight – 2022
News | June 14, 2022

Dr. Bharati Pravin Pawar launches Intensified Diarrhoea Control Fortnight – 2022

The IDCF programme is being implemented from 13th June to 27th June, 2022 in the states/UTs and the goal is to attain zero child deaths due to childhood diarrhoea


Strides receives USFDA approval for Ibuprofen OTC oral suspension
Drug Approval | June 12, 2022

Strides receives USFDA approval for Ibuprofen OTC oral suspension

Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.


Bayer’s Vividion emerging as significant player in San Diego Biotech hub
Biotech | June 10, 2022

Bayer’s Vividion emerging as significant player in San Diego Biotech hub

Bayer now present in four of the largest biotechnology hubs in the United States


Sumitomo Pharma Oncology receives orphan drug designation for the treatment of myelofibrosis
Drug Approval | June 09, 2022

Sumitomo Pharma Oncology receives orphan drug designation for the treatment of myelofibrosis

TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.


Eugia Pharma receives USFDA Approval for Leuprolide Acetate Injection
Drug Approval | June 08, 2022

Eugia Pharma receives USFDA Approval for Leuprolide Acetate Injection

he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.


LEO Pharma strengthens its commercial organization
News | June 03, 2022

LEO Pharma strengthens its commercial organization

The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally